🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 22 of 116

  1. Taxotere , Epirubicin

    Hospital Authority, Hong Kong

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  2. Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Cancer (Future parent protocols may include other cancer that are not included in this section)

    phase 3 small molecule active

    1 trial

  3. Tecentriq 1 200 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.

    phase 3 small molecule active

    1 trial

  4. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

    phase 3 small molecule active

    1 trial

  5. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    Hoffmann-La Roche

    High-risk hepatocellular carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  6. Tecentriq 1 200 mg concentrate for solution for infusion, CISPLATIN , CARBOPLATIN , BNT327, ETOPOSIDE

    BioNTech SE

    English First-line extensive-stage small-cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  7. Tecentriq 1 200 mg concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BI 764532, RoActemra 20 mg/mL concentrate for solution for infusion

    Boehringer Ingelheim

    small cell lung cancer

    phase 3 small molecule active

    1 trial

  8. Tecentriq 1 200 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq placebo

    Hoffmann-La Roche

    Early human epidermal growth factor receptor 2 (HER2) positive breast cancer

    phase 3 small molecule active

    1 trial

  9. Tecentriq 1 200 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tiragolumab placebo, Tiragolumab

    Hoffmann-La Roche

    Non-squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  10. Tecentriq 1 200 mg concentrate for solution for infusion, LURBINECTEDIN, RO7508182

    Hoffmann-La Roche

    Small-Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  11. Tecentriq 1 200 mg concentrate for solution for infusion, PACLITAXEL, CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  12. Tecentriq 840 mg concentrate for solution for infusion

    Novo Nordisk A/S

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 3 small molecule active

    1 trial

  13. Tecentriq Placebo, Abraxane 5 mg/ml powder for dispersion for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml Intravenous Infusion, Cisplatin 1mg/ml concentrate for solution for infusion

    Hoffmann-La Roche

    Early-Stage Resectable Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  14. Tecentriq concentrate for solution for infusion placebo 0mg, Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    High-risk muscle-invasive bladder cancer

    phase 3 small molecule active

    1 trial

  15. Tegafur-Gimeracil-Oteracil Potassium

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stomach Neoplasm

    phase 3 small molecule completed

    1 trial

  16. Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)

    Eastern Hepatobiliary Surgery Hospital

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial

  17. Telisotuzumab Adizutecan

    AbbVie

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. Telisotuzumab Vedotin, DOCETAXEL

    AbbVie Deutschland GmbH & Co. KG

    c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  19. Temomedac 20 mg hard capsules, Temomedac 5 mg hard capsules, Tirabrutinib, Temomedac 100 mg hard capsules, Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/refractory primary central nervous system lymphoma

    phase 3 small molecule active

    1 trial

  20. Thalidomide

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  21. The placebo tablet composition is: Collodial silicone dioxide, Magnesium stearate, Carmellose sodium, Cellulosa powder. Appearance and size will be the same for active and placebo., Trombyl 160 mg tabletter

    The George Institute

    Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN

    phase 3 small molecule active

    1 trial

  22. Tiaoshen Anti-cancer Granules

    The First People's Hospital of Lianyungang

    Ovarian Neoplasms Malignant

    phase 3 small molecule active

    1 trial

  23. Tibsovo 250 mg film-coated tablets

    The George Institute

    ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  24. Tinidazole oral microneedle patch

    The First People's Hospital of Lianyungang

    Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis

    phase 3 other active

    1 trial

  25. Tiragolumab

    Hoffmann-La Roche

    Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  26. Tiragolumab Placebo, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab, Tecentriq Placebo

    Hoffmann-La Roche

    Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  27. Tiragolumab, Placebo Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  28. Tislelizumab

    BeiGene

    Recurrent or Metastatic Nasopharyngeal Cancer

    phase 3 small molecule completed

    1 trial

  29. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Classical Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  30. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colonic Neoplasms

    phase 3 small molecule active

    1 trial

  31. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 small molecule completed

    1 trial

  32. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    4 trials

  33. Tislelizumab

    The First People's Hospital of Lianyungang

    Rectal Neoplasms

    phase 3 small molecule active

    1 trial

  34. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

  35. Tislelizumab

    BeiGene

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    2 trials

  36. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Rectal Carcinoma

    phase 3 small molecule active

    1 trial

  37. Tislelizumab + SOX Chemotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 3 small molecule active

    1 trial

  38. Tislelizumab 300 mg solution for injection, Tevimbra 100 mg concentrate for solution for infusion

    BEONE MEDICINES AUS PTY LTD

    Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

    phase 3 small molecule active

    1 trial

  39. Tislelizumab（neoadjuvant）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinomas

    phase 3 small molecule active

    1 trial

  40. Topotecan HEXAL 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Anastrozol STADA® 1 mg Filmtabletten, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, VS-6766, LETRO-cell® 2,5 mg Filmtabletten, VS-6063, Letrozol - 1 A Pharma® 2,5 mg Filmtabletten, ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for inf

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 3 small molecule active

    1 trial

  41. Tora-Dol 30 mg/ml soluzione iniettabile, Acido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti, SODIO CLORURO 0,9% BAXTER Soluzione per infusione

    Fondazione Telethon ETS

    Patients scheduled for major surgery for oncologic indication

    phase 3 small molecule active

    1 trial

  42. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    2 trials

  43. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  44. Trabectedin

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  45. Trabectedin EVER Pharma 1 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Pazopanib PharOS 200 mg film-coated tablets, HALAVEN 0.44 mg/ml solution for injection

    INTENSITY THERAPEUTICS, INC.

    liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), Leiomyosarcoma (non-uterine), Undifferentiated pleomorphic sarcoma

    phase 3 small molecule active

    1 trial

  46. Trastuzumab

    Mylan IRE Healthcare Limited

    Breast Cancer

    phase 3 mab completed

    1 trial

  47. Trastuzumab

    Celltrion Healthcare Australia Pty Ltd

    HER2-positive Carcinoma of Breast

    phase 3 small molecule completed

    1 trial

  48. Trastuzumab

    Hoffmann-La Roche

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.